Muscle atrophy and weakness are prevalent features of cancer. Although extensive research has characterized skeletal muscle wasting in cancer cachexia, limited studies have investigated how cardiac structure and function are affected by therapy-naive cancer. Herein, orthotopic, syngeneic models of epithelial ovarian cancer and pancreatic ductal adenocarcinoma, and a patient-derived pancreatic xenograft model, were used to define the impact of malignancy on cardiac structure, function, and metabolism. Tumor-bearing mice developed cardiac atrophy and intrinsic systolic and diastolic dysfunction, with arterial hypotension and exercise intolerance. In hearts of ovarian tumor-bearing mice, fatty acid-supported mitochondrial respiration decreased, and carbohydrate-supported respiration increased-showcasing a substrate shift in cardiac metabolism that is characteristic of heart failure. Epithelial ovarian cancer decreased cytoskeletal and cardioprotective gene expression, which was paralleled by down-regulation of transcription factors that regulate cardiomyocyte size and function. Patient-derived pancreatic xenograft tumor-bearing mice show altered myosin heavy chain isoform expression-also a molecular phenotype of heart failure. Markers of autophagy and ubiquitin-proteasome system were upregulated by cancer, providing evidence of catabolic signaling that promotes cardiac wasting. Together, two cancer types were used to cross-validate evidence of the structural, functional, and metabolic cancer-induced cardiomyopathy, thus providing translational evidence that could impact future medical management strategies for improved cancer recovery in patients.
1 January 2023 in American Journal of Physiology-Heart and Circulatory Physiology
Cardiac reserve is a globally used health indicator and prognostic tool that is used by clinicians and preclinical scientists. In physiology, we have a long-standing appreciation of how to assess systolic reserve but lack insight into sex differences and have no frame of reference for measuring diastolic reserve to certainty across cardiac techniques or the influence of sex. Here, we show that the primary means for assessing diastolic reserve is incorrect. Furthermore, we provided proof and clarity on how to correctly measure systolic and diastolic reserve capacities. We also highlight the imperative of sex differences to the measures of both systolic and diastolic reserves using several techniques (i.e., echocardiography, invasive hemodynamics, and Langendorff) in mice.
1 June 2024 in American Journal of Physiology-Heart and Circulatory Physiology
Cardiovascular disease (CVD) and cancer are the leading causes of mortality worldwide. Although generally thought of as distinct diseases, the intersectional overlap between CVD and cancer is increasingly evident in both causal and mechanistic relationships. The field of cardio-oncology is largely focused on the cardiotoxic effects of cancer therapies (e.g., chemotherapy, radiation). Furthermore, the cumulative effects of cardiotoxic therapy exposure and the prevalence of CVD risk factors in patients with cancer lead to long-term morbidity and poor quality of life in this patient population, even when patients are cancer-free. Evidence from patients with cancer and animal models demonstrates that the presence of malignancy itself, independent of cardiotoxic therapy exposure or CVD risk factors, negatively impacts cardiac structure and function. As such, the primary focus of this review is the cardiac pathophysiological and molecular features of therapy-naïve cancer. We also summarize the strengths and limitations of preclinical cancer models for cardio-oncology research and discuss therapeutic strategies that have been tested experimentally for the treatment of cancer-induced cardiac atrophy and dysfunction. Finally, we explore an adjacent area of interest, called “reverse cardio-oncology,” where the sequelae of heart failure augment cancer progression. Here, we emphasize the cross-disease communication between malignancy and the injured heart and discuss the importance of chronic low-grade inflammation and endocrine factors in the progression of both diseases.
The prevalence of child obesity is a worldwide public health concern. Good sleep quality is associated with reduced adiposity in older children and adults. More research is needed in younger children to help mitigate risk of obesity. In addition, we aimed to address limitations found in previous studies such as relying on subjective measures, or only including one parameter of sleep, using only one body composition parameter, and/or not adjusting for relevant covariates. This cross-sectional study examined baseline data from 48 toddlers aged 1 to <3 years enrolled in the Guelph Family Health Study. Nighttime sleep duration (total sleep time; TST), sleep timing (sleep onset and offset time), and sleep quality (wake after sleep onset; WASO) were measured using 24 h accelerometry for 7 consecutive days. Height, body weight, and waist circumference were measured, and BMI z-scores and waist-to-height ratios were calculated. Percent fat mass and fat mass index were calculated using bioelectrical impedance analysis. Linear regression models were used to estimate associations between sleep parameters and body composition outcomes, with adjustments for relevant covariates (age, sex, household income, screen time, energy intake, physical activity, household stress). Nighttime sleep onset time was positively associated with waist-to-height ratio ([ ] = 0.004, p = 0.04). Sleep offset time was negatively associated with BMI z-score ([ ] = −0.48, p = 0.02). TST and WASO were not associated with any body composition outcome. Building healthy sleep habits may prevent childhood obesity; longitudinal research in a larger sample is warranted. This study was registered on ClinicalTrials.gov (NCT02939261).